U.S. Ranbaxy Court Action Stirs Concern In Indian Drug Industry
This article was originally published in PharmAsia News
India's generic drug industry is concerned U.S. government accusations of adulterated drugs marketed by Ranbaxy Laboratories could have a widespread effect. Some industry representatives expect anti-generics lobbyists to take advantage of the lawsuit. The industry experts also believe the entire Indian drug-making industry, which has enjoyed a good safety record, could become viewed with caution. There also is the possibility of medical professionals around the world becoming suspicious of Indian products. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.